Price Don’t Lie: What’s Next for Tetraphase Pharmaceuticals Inc After Touching 52-Week Low?

Price Don't Lie: What's Next for Tetraphase Pharmaceuticals Inc After Touching 52 Week Low?

The stock of Tetraphase Pharmaceuticals Inc (NASDAQ:TTPH) hit a new 52-week low and has $3.03 target or 10.00% below today’s $3.37 share price. The 8 months bearish chart indicates high risk for the $123.67 million company. The 1-year low was reported on Nov, 4 by Barchart.com. If the $3.03 price target is reached, the company will be worth $12.37 million less.
The 52-week low event is an important milestone for every stock because it shows very negative momentum and is time when sellers come in. During such technical setups, fundamental investors usually stay away and are careful buying the stock. About 154,826 shares traded hands. Tetraphase Pharmaceuticals Inc (NASDAQ:TTPH) has declined 32.29% since April 4, 2016 and is downtrending. It has underperformed by 33.38% the S&P500.

Analysts await Tetraphase Pharmaceuticals Inc (NASDAQ:TTPH) to report earnings on November, 7. They expect $-0.49 earnings per share, 0.00% or $0.00 from last year’s $-0.49 per share. After $-0.47 actual earnings per share reported by Tetraphase Pharmaceuticals Inc for the previous quarter, Wall Street now forecasts 4.26% negative EPS growth.

Tetraphase Pharmaceuticals Inc (NASDAQ:TTPH) Ratings Coverage

Out of 11 analysts covering Tetraphase Pharmaceuticals (NASDAQ:TTPH), 1 rate it a “Buy”, 0 “Sell”, while 10 “Hold”. This means 9% are positive. Tetraphase Pharmaceuticals has been the topic of 15 analyst reports since August 6, 2015 according to StockzIntelligence Inc. The firm has “Buy” rating given on Thursday, August 6 by Brean Capital. As per Wednesday, September 9, the company rating was downgraded by Cantor Fitzgerald. The stock has “Neutral” rating given by Robert W. Baird on Wednesday, September 9. The firm has “Market Perform” rating given on Tuesday, April 12 by BMO Capital Markets. As per Thursday, August 6, the company rating was maintained by Needham. The stock of Tetraphase Pharmaceuticals Inc (NASDAQ:TTPH) earned “Hold” rating by Stifel Nicolaus on Wednesday, September 9. The stock of Tetraphase Pharmaceuticals Inc (NASDAQ:TTPH) earned “Neutral” rating by Gabelli on Friday, May 13. The firm has “Market Perform” rating given on Wednesday, September 9 by JMP Securities. Wedbush downgraded Tetraphase Pharmaceuticals Inc (NASDAQ:TTPH) on Wednesday, September 9 to “Neutral” rating. Nomura downgraded the stock to “Neutral” rating in Wednesday, September 9 report.

According to Zacks Investment Research, “Tetraphase Pharmaceuticals, Inc. is a life science company engaged in developing and commercializing tetracycline based drugs to treat drug-resistant infectious diseases, inflammation, and cancer. Its principal products include eravacycline, an intravenous and oral antibiotic for the treatment of multi-drug resistant Gram-negative infections. The Company’s product under development includes eravacycline oral formulation, TP-834 and TP-271. Tetraphase Pharmaceuticals, Inc. is based in Watertown, Massachusetts.”

Insitutional Activity: The institutional sentiment decreased to 0.86 in 2016 Q2. Its down 0.31, from 1.17 in 2016Q1. The ratio fall, as 18 funds sold all Tetraphase Pharmaceuticals Inc shares owned while 26 reduced positions. 14 funds bought stakes while 24 increased positions. They now own 21.31 million shares or 7.27% less from 22.99 million shares in 2016Q1.
Tiaa Cref Management Lc last reported 230,758 shares in the company. Wells Fargo And Mn reported 14,402 shares or 0% of all its holdings. Putnam last reported 75,000 shares in the company. Rhumbline Advisers holds 0% or 57,435 shares in its portfolio. California State Teachers Retirement Sys accumulated 76,320 shares or 0% of the stock. Blackrock holds 0% of its portfolio in Tetraphase Pharmaceuticals Inc (NASDAQ:TTPH) for 8,267 shares. Manchester Cap Mgmt has invested 0% of its portfolio in Tetraphase Pharmaceuticals Inc (NASDAQ:TTPH). Federated Investors Pa holds 0% or 93,303 shares in its portfolio. Wellington Mngmt Group Inc Ltd Liability Partnership reported 2.47M shares or 0% of all its holdings. Acadian Asset Ltd Co holds 0% or 59,986 shares in its portfolio. Schwab Charles Inv Mngmt Inc owns 113,453 shares or 0% of their US portfolio. Manufacturers Life Insur The holds 0% or 28,423 shares in its portfolio. Granahan Inv Management Ma, a Massachusetts-based fund reported 686,921 shares. State Board Of Administration Of Florida Retirement holds 0% or 19,717 shares in its portfolio. Renaissance Technology Lc has 784,805 shares for 0.01% of their US portfolio.

More notable recent Tetraphase Pharmaceuticals Inc (NASDAQ:TTPH) news were published by: Fool.com which released: “Why Tetraphase Pharmaceuticals Inc Stock Was Annihilated Today” on September 09, 2015, also Marketwatch.com with their article: “Tetraphase’s stock tumbles 21% to record low” published on April 15, 2013, Fool.com published: “Why Tetraphase Pharmaceuticals Dropped 74% of Its Value in 2015” on January 11, 2016. More interesting news about Tetraphase Pharmaceuticals Inc (NASDAQ:TTPH) were released by: Globenewswire.com and their article: “Tetraphase Pharmaceuticals Reports Second Quarter 2016 Financial Results and …” published on August 04, 2016 as well as Quotes.Wsj.com‘s news article titled: “News Tetraphase Pharmaceuticals Inc.TTPH” with publication date: March 22, 2013.

TTPH Company Profile

Tetraphase Pharmaceuticals, Inc. (Tetraphase), incorporated on July 7, 2006, is a clinical-stage biopharmaceutical company. The Firm uses its chemistry technology to create antibiotics for multidrug-resistant infections. The Firm is developing its lead product candidate, eravacycline, a fully synthetic tetracycline derivative, as a spectrum intravenous (IV) and oral antibiotic for use as a first-line empiric monotherapy for the treatment of multidrug-resistant infections, including multidrug-resistant Gram-negative infections. The Firm also develops TP-6076 for multidrug-resistant Gram- negative infections.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Related posts

Leave a Comment